Research
312 results
Name Type Target Compound Name Phase
IMV

IMV has used sequences of the virus and immuno-informatics to predict and identify several hundred epitopes, of which 23 were selected for their biological relevance to the virus and potential to generate neutralizing antibodies against SARS-CoV-2

New Therapies (Antibody-based) SARS-CoV-2 spike protein DPX-COVID-19 Pre-Clinical
Kleo Pharmaceuticals

Kleo’s First Non-Oncology Application of Its Antibody Recruiting Molecule (ARM™) to Be Tested in Combination with GCLC’s NK Cells as a Potential COVID-19 Therapeutic

New Therapies (Antibody-based) SARS-CoV-2 spike protein Hyperimmune globulin mimic (HGM) Pre-Clinical
University of California, San Diego

Marrying Molecular Farming and Advanced Manufacturing to Develop a COVID-19 Vaccine

Vaccine (Attenuated) SARS-CoV-2 spike protein Plant virus nanotechnology Pre-Clinical
Sorrento Therapeutics

STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus

Vaccine (Attenuated) SARS-CoV-2 spike protein STI-6991 Pre-Clinical
Sorrento Therapeutics

STI-4398 (COVIDTRAP) protein to immediately commence testing its neutralization and blocking activity in preventing SARS-CoV-2 virus from infecting ACE2-expressing cells

New Therapies (Protein-based) SARS-CoV-2 spike protein STI-4398 Pre-Clinical
Collaboration: Vir Biotechnology & GSK

Identification of novel SARS CoV2 binding monoclonal antibodies

New Therapies (Antibody-based) SARS-CoV-2 spike protein VIR-7832 Pre-Clinical
Harbour BioMed

Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise

New Therapies (Antibody-based) SARS-CoV-2 spike protein 47D11 Pre-Clinical
Massachusetts Institute of Technology (MIT)

Using Ai to analyze the spike protein present on SARs-CoV-2

Research (AI) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Pre-Clinical
Collaboration: Massachusetts Institute of Technology, Harvard University, and Biobot Analytics

Wastewater analysis to track the spread of SARS-CoV-2

Research (Epidemiology) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Research
University of Michigan

3D structural models of all proteins encoded by the genome of SARS-CoV-2

Research (Modeling) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Research
Michigan State University

Computational approaches to identify drugs inhibit SARS-CoV-2

Research (Drug Repurposing) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Pre-Clinical
RUCDR Infinite Biologics / Accurate Diagnostic Labs

New saliva SARS-CoV-2 test

Research (Testing Kits) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Pre-Clinical
University of Pennsylvannia

Investigation of SARS-CoV-2 and the Lung Microbiome

Research (Epidemiology) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Pre-Clinical
University of Pennsylvannia

Investigation of host innate immune responses to SARS-CoV-2

Research (Modeling) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Research
Collaboration: Apeiron Biologics & The University of British Columbia

APN01 is therecombinantform of thehuman angiotensin-converting enzyme 2 (rhACE2), and has the potential toblock the infection ofcellsby the novel SARS-CoV-2 virus (COVID-19), and reduce lung injury.

New Therapies (Protein-based) SARS-CoV-2 spike protein (SARS-CoV-2 S) APN01 Phase I / II
Innovation Pharmaceuticals

Use of brilacidin, a bacterial defensin mimetic, to treat Coivd-19

Research (Drug Repurposing) SARS-CoV-2 spike protein (SARS-CoV-2 S) Brilacidin Phase II
Integral Molecular

Identification of >1,000 potential antibody binding sites on SARS CoV2

Research (Modeling) SARS-CoV-2 spike protein (SARS-CoV-2 S) Unnamed Research
Baylor College of Medicine

Dynamics of SARS-CoV2 spike protein RBD and core S2 domains

Research (Modeling) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Pre-Clinical
McMaster University

In this project, a novel City Dynamic Network Analysis (CityDNA) model will be developed to generate optimal city operation schemes in the face of COVID-19. By leveraging state-of-the-art techniques in network science, machine learning, systems analysis, and multi-objective optimization, the proposed CityDNA model will provide a unique decision support tool for optimizing the operation and/or reopening of municipal facilities (e.g. transit systems, parks, community centers, and schools) under complex constraints due to current and future COVID-19 pandemics. This project intends to provide innovative solutions to mitigate the risk of lasting economic and social damages caused by COVID-19 in cities across Canada.

Research (AI) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Research
McGill University

Long-term care (LTC) homes are being disproportionately affected by COVID-19. This project will implement proven remote monitoring technology empowered with Artificial Intelligence to track, monitor and predict senior residents’ symptoms. The detection and prediction of asymptomatic changes will facilitate rapid isolation and can save thousands of lives. The technology will alert the providers when COVID-19 symptoms are identified/predicted and monitor any decompensation. This project will monitor 60 senior residents in two LTC homes (Toronto and Montreal) and then scale up for the entire LTC homes, and intends to protect LTC home staff and frail residents from exposure to COVID-19 by enabling remote monitoring.

Research (AI) SARS-CoV-2 spike protein (SARS-CoV-2 S) N/A Research
Zhongnan Hospital of Wuhan University

Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2

SARS-Cov-2 protein IgG Antibodies Research
Ansun Biopharma

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

New Therapies (Protein-based) Sialic acid FluDase (DAS181) Phase III
Collaboration: University of Oxford; National Institute of Health (NIH)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Vaccine (Viral Vector) Spike protein of SARS-CoV-2 ChAdOx1 Phase I
Collaboration: Valneva; Dynavax

Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 provides a well‑developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.

Vaccine (Attenuated) Toll-like receptor 9 VLA2001 Pre-Clinical
Mateon Therapeutics

A TGF-Beta antisense drug candidate for Covid 19 treatment

Vaccine (Nucleic Acid-based) Transforming growth factor (TGF) beta 2 (TGFB2) OT-101 Pre-Clinical